STAT+: FTC tells Illumina to divest Grail, boosting Icahn’s case
The U.S. Federal Trade Commission on Monday ordered DNA sequencing giant Illumina to divest Grail, a cancer diagnostics firm it purchased without regulatory approval.
The U.S. Federal Trade Commission on Monday ordered DNA sequencing giant Illumina to divest Grail, a cancer diagnostics firm it purchased without regulatory approval, saying the $7.1 billion acquisition “would stifle competition and innovation in the U.S. market for life-saving cancer tests.”
Illumina purchased Grail in August 2021 without clearances from either the FTC or European regulators, who also appear to be preparing to tell Illumina to divest the cancer diagnostics firm.
What's Your Reaction?
